31
Aug
2021
Meet the Climb to Fight Cancer Postdoctoral Fellow: Aleena Arakaki
I’m excited to announce that the first Climb to Fight Cancer postdoctoral fellow has been selected. This is a position designed to advance the careers of young scientists from traditionally underrepresented minority groups. Aleena Arakaki is the first recipient of this postdoctoral award. She is a Kanaka Maoli (Native Hawaiian) woman. Before describing Arakaki’s background and research, here’s what the... Read More
31
Aug
2021
Atlas, Medicxi Invest $70M in Antibody for Obesity Licensed from Novartis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Aug
2021
Pfizer / BioNTech Vaccine Approved, Lilly Works With Lycia, & We Wait for J&J
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Aug
2021
Giving Back and Experiencing Nature
Sometimes we need to get away from work, and the news, to recharge our batteries. August is traditionally that time of year for me. I just got back from the summit of Mt. Baker (elevation 10,781 ft) in the North Cascades of Washington. It was another successful mountain trip with terrific biotech people – entrepreneur Julia Owens, investor Dan Bradbury,... Read More
9
Aug
2021
Better Cancer Drugs for Kids: Julie Grant and Sam Blackman on The Long Run
Today we have a pair of guests on The Long Run — Julie Grant and Sam Blackman. Julie is a venture capitalist – a general partner at Canaan Partners. Sam is a pediatric oncologist and drug developer. After a routine business meeting, they realized they had something in common. They both believed that the pharmaceutical industry can — and should... Read More
5
Aug
2021
Bayer Snaps Up Vividion, Sanofi Grabs Translate Bio, and RIP: Tachi Yamada
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2021
Tachi Yamada, Physician-Scientist-Biopharma Industry Leader, Dies at 76
Tadataka “Tachi” Yamada, a distinguished physician-scientist who became a biopharmaceutical industry leader and a deeply respected advisor to biotech entrepreneurs, died the morning of Aug. 4. He was 76. Yamada died from a heart attack while exercising at home in Seattle, said his son, Takao. “He was a special person who did things to help people. That was his North... Read More
29
Jul
2021
FDA Rejections, Midsummer IPOs & Amgen’s Bispecific Buy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Jul
2021
Career Arc of a Biotech Leader: Sue Desmond-Hellmann on The Long Run
Today’s guest on The Long Run is Sue Desmond-Hellmann. Sue — and I don’t say this about many people — is a biotech industry legend. Sue is an oncologist and a public health professional by training. She made her name in biopharmaceuticals at Genentech from 1995-2009 — the glory days when it became the world’s most important developer of new... Read More
22
Jul
2021
Biogen’s Bumbling Defense, Delta on the Move, & PacBio’s Power Play
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Jul
2021
Investing at the Nexus of Biology & Technology: Jenny Rooke on The Long Run
Today’s guest on The Long Run is Jenny Rooke. Jenny is the founder and managing partner of San Francisco-based Genoa Ventures. I’ve been wanting to invite Jenny on the podcast for a while. Back in 2018, I profiled her as one of “Nine VCs Who Matter, But You Never Read About.” As I wrote then: “VCs take on lots of... Read More
15
Jul
2021
Payers Revolt Against Biogen’s Aduhelm, FDA Credibility Crisis, and a Prime Financing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jul
2021
Verge Genomics Strikes Deal with Lilly to Validate New Targets for ALS
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Jul
2021
Biogen’s Perilous Path, Intellia’s In Vivo Milestone, & Holiday Financings
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jun
2021
Lander Pushes ARPA-H, Lilly Follows Fast in Alzheimer’s, & Wyden Moderates on Price
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jun
2021
EQRx, Exscientia Team Up to Accelerate R&D for Lower-Priced, Better Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jun
2021
Novavax Nails Vaccine Trial, CureVac Fails, & Flagship Sails on With $3.4B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jun
2021
On Juneteenth, Honoring 22 Black Biotech Leaders
A few Black people have risen to prominence in biopharma. Ken Frazier, Tony Coles, Rob Perez and Ted Love are among the most visible. But there are many other Black leaders in the industry who are making important contributions to the science and business of human health. Today, let’s recognize the Juneteenth holiday coming up June 19. It’s a celebration... Read More
15
Jun
2021
Mentoring Young Scientists: Jay Bradner and Andy Plump on The Long Run
This episode of The Long Run is a little different. I invited a couple previous guests on The Long Run to discuss a specific issue: How the industry can do a better job of mentoring young scientists, and creating on-ramps to careers in the biopharma industry for people from underrepresented groups. Jay Bradner, the president of the Novartis Institutes for... Read More
14
Jun
2021
Biotech Pride: 19 Industry Leaders Who Identify as LGBTQ
Scientists have created mRNA vaccines that are saving millions of lives. Better cancer drugs are in the works. Gene editing technologies, and gene therapies, offer potential cures. Teams of dedicated people are making these things happen, and many of the people on these teams identify as LGBTQ. As part of Pride Month, I asked TR readers to nominate members of... Read More